EMBLA — Embla Medical hf Income Statement
0.000.00%
- DKK12.65bn
- DKK15.97bn
- $785.68m
- 72
- 22
- 48
- 42
Annual income statement for Embla Medical hf, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 686 | 630 | 719 | 719 | 786 |
Cost of Revenue | |||||
Gross Profit | 439 | 391 | 455 | 440 | 486 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 589 | 601 | 621 | 654 | 696 |
Operating Profit | 97.7 | 28.3 | 97.3 | 64.8 | 89.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 90.3 | 12.7 | 86.6 | 56.2 | 76 |
Provision for Income Taxes | |||||
Net Income After Taxes | 68.9 | 7.92 | 65.7 | 43.2 | 58.8 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 66 | 6.21 | 64 | 42.5 | 58.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 66 | 6.21 | 64 | 42.5 | 58.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.17 | 0.04 | 0.152 | 0.102 | 0.139 |
Dividends per Share |